ArticleBMC infectious diseases2025
The resurgence of malaria in Northern Iran in 2023: a wake-up call.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiological and clinical profile of malaria patients in Isfahan Province, Iran: a retrospective analysis from 2009 to 2025.Malaria journal · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundControl and elimination programs for malaria in Iran have consistently faced significant challenges due to various factors, including the presence of neighboring malaria-endemic countries such as Afghanistan and Pakistan. In recent years, Golestan Province in northern Iran has recorded few cases of imported malaria, with a sudden increase of 22 cases in 2023. This article provides an overview of the malaria situation in northern Iran, along with a detailed report of these 22 cases.
methodsThe study population comprises all individuals exhibiting symptoms suspected of malaria (n = 445) who were referred to the Malaria Diagnosis Center in Golestan Province, located in northeastern Iran, for diagnosis between March 23, 2023, and December 23, 2023. A drop of peripheral blood, collected from a finger prick of each patient, was utilized for Plasmodium falciparum/P. vivax antigen detection. Moreover, thin and thick smears were prepared for each patient to investigate morphological characteristics and parasitemia percentage of the parasites.
resultsIn total, 4.94% (22/445) of individuals with malaria-suspected symptoms were infected with Plasmodium species. All 22 infected individuals were native to Golestan Province, and none had a previous history. The mean ± standard error of mean (SEM) for the number of parasites/µL of blood sample was 16,029 ± 5,060 for P. vivax and 105,460 ± 102,146 for P. falciparum. Among the patients, 77.27% (17/22) were infected with P. vivax, 18.18% (4/22) were infected with P. falciparum, and 4.54% (1/22) were co-infected with both P. vivax and P. falciparum. In the case of P. falciparum, 40% (1/5) of the samples presented the ring form, 60% (3/5) trophozoite form, and 20% (1/5) gametocyte form. All patients demonstrated a positive response to the treatment, with a decrease in both the number of parasites and the number of clinical symptoms over time.
conclusionsThis study discussed 22 cases of malaria diagnosed in 2023 in Golestan Province in northern Iran. Given the presence of malaria vectors in this area and the observation of gametocytes in specimens from some patients, the increase in reported malaria cases could be worrisome in terms of establishing local transmission in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.